Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNQ-701
- Development stage
- Preclinical
- Lead developer
- Impetis Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PNQ-701 is a selective Janus kinase 1 (JAK1) inhibitor being developed by Impetis Biosciences for the treatment of rheumatoid arthritis. As an oral small molecule, it is engineered to provide high selectivity for the JAK1 isoform while exhibiting minimal inhibition of JAK2 and JAK3. This selectivity profile is intended to reduce the risk of adverse events typically associated with pan-JAK inhibitors, such as anemia or neutropenia, which are often linked to JAK2 and JAK3 inhibition. The asset has been licensed to Vyome Holdings for further development and is currently in the IND-enabling phase, with plans to be IND-ready in the near future.
02
Targets
Beyond the preview
Go deeper on PNQ-701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNQ-701.